Cartesian Therapeutics Strengthens Leadership Team With Appointment Of Carsten Brunn, Ph.D., As Chairman Of The Board

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, has announced a key leadership change. The company named Carsten Brunn, Ph.D., as Chairman of the Board of Directors, effective October 29, 2025. Dr. Brunn currently serves as Cartesian’s President, Chief Executive Officer, and a member of the Board. He succeeds Carrie S. Cox, who has decided to step down to focus on other professional responsibilities, including her recent appointment as Executive Chair of another publicly traded company.

In conjunction with this transition, Patrick Zenner, M.B.A., has been appointed as Lead Independent Director of the Board, reinforcing the company’s commitment to strong corporate governance and experienced leadership. Commenting on the transition, Dr. Brunn expressed his gratitude for Ms. Cox’s guidance and leadership over the years. “Carrie’s contributions as Chairman of the Board have been instrumental in advancing Descartes-08 to where it is today,” he said. “We are grateful for her knowledge and guidance, and we wish her the very best as she focuses on her other commitments.”

Reflecting on her tenure, Ms. Cox shared her optimism about Cartesian’s future. “I firmly believe that Cartesian is on the precipice of expanding the reach of potentially transformative cell therapies to autoimmune diseases, and it has been an honor to be part of their exciting journey thus far,” she said. “With a deeply experienced team possessing a broad range of expertise across the entirety of the drug development continuum, I am confident that Cartesian is well positioned for continued success as they advance closer toward their first planned regulatory submission for Descartes-08 and, ultimately, subject to approval, a successful commercial launch.”

This leadership update marks an important moment for Cartesian Therapeutics as it continues its mission to redefine treatment possibilities for autoimmune diseases through innovative cell therapy approaches.